Latest Research And Development News

Venus Metals has unveiled promising auger soil sampling results at its Henderson Gold Project and significant base metals anomalies at Youanmi, alongside initiating a titanium extraction research program with Murdoch University.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Elixir Energy has successfully completed a key pressure test on its Lorelle-3H well in Queensland’s Taroom Trough, confirming reservoir conditions and increasing planned stimulation stages from 11 to 12. Stimulation operations are set to start imminently, aiming to prove commercial gas and condensate flow.

Temas Resources is on track to fully commission its Ontario metallurgical lab by July 2026, initiating large-scale testing of La Blache project material to refine its proprietary RCL technology and support commercialization.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

Elixir Energy has kicked off the stimulation and testing phase at its Lorelle-3H appraisal well, aiming to validate commercial gas and condensate flow rates from Queensland’s Taroom Trough basin-centred gas play.